The effect of bone marrow reticulin fibrosis degree at diagnosis on the success of intensive and reduced Intensity Induction therapy in de novo AML patients: retrospective single-center study
Hematology in Clinical Practice, cilt.16, ss.52-61, 2025 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 16
- Basım Tarihi: 2025
- Doi Numarası: 10.5603/hicp.101732
- Dergi Adı: Hematology in Clinical Practice
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.52-61
- Anahtar Kelimeler: acute myeloid leukemia, fibrosis, induction, reticulin
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: This study aimed to investigate the potential effect of bone marrow reticulin fibrosis (BMF) on laboratory values, induction therapy success, and survival in patients with AML receiving either intensive remission induction chemotherapy (IC) or reduced-intensity chemotherapy (RIC). Materials and methods: A total of 178 patients diagnosed with de novo AML were included in the study between 2016 and 2023. Patients were categorized into two groups: IC and RIC. Induction treatment success, neutrophil and platelet recovery times, survival data, and improvement in fibrosis were compared between patients with and without BMF at the time of diagnosis. Results: Among the 178 patients, 66.9% had grade ≥ 1 BMF at diagnosis. There was no statistically significant difference in laboratory data (peripheral leukocyte count, serum LDH level, and bone marrow blast percentage; P = 0.911, P = 0.147, and P = 0.723, respectively) between those with and without BMF. Remission rates after induction therapy were also similar (RIC: P = 0.523; IC: P = 0.421). No significant difference was found in neutrophil or platelet recovery times after induction therapy (IC patients: P = 0.910 and P = 0.260, respectively). There was no statistically significant difference in overall survival, relapse-free survival, or bone marrow transplantation rates between those with and without BMF (IC patients: P = 0.724, P = 0.429, and P = 0.616, respectively; RIC patients: P = = 0.141, P = 0.157, and P = 1.0, respectively). The rate of regression in BMF grade was 17.5% in the IC group and 8.5% in the RIC group. Conclusions: Regardless of treatment intensity in patients with de novo AML, BMF has been shown not to affect laboratory findings at diagnosis, induction treatment success, or survival outcomes.